2026-06-02 カリフォルニア大学アーバイン校（UCI）
＜関連情報＞
- https://news.uci.edu/2026/06/02/uc-irvine-study-identifies-serious-infection-risks-linked-to-targeted-cancer-therapies/
- https://www.mdpi.com/2072-6694/18/10/1563
抗体薬物複合体に関連する臨床的に重要な好中球減少症および合併症の発生率：カリフォルニア大学における実臨床研究 Incidence of Clinically Significant Neutropenia and Complications Related to Antibody-Drug Conjugates: A Real-World Study at the University of California
Tiffany Jan,Miranda Chen,Fan-Ying Chan,Nicole Kuderer and Alexandre Chan
Cancers Published: 12 May 2026
DOI:https://doi.org/10.3390/cancers18101563
Simple Summary
Antibody-drug conjugates are cancer treatments that deliver powerful chemotherapy directly to tumor cells, reducing harm to healthy tissue. While these drugs can be more effective and safer than traditional chemotherapy, they can still cause serious side effects, in particular low white blood cell counts, which increase infection risk and hospital visits. In this study, we analyzed real-world data from 3511 patients across six University of California hospitals to understand how often these blood-related complications occur with different antibody-drug conjugates. We found that the risk of serious infections and low white blood cells varied widely depending on the drug, and certain conditions, like anemia or weakened immunity, increased the risk. These findings can help doctors better monitor and manage side effects and provide insights for researchers developing safer and more effective targeted cancer therapies.
Abstract
Background/Objectives: Using real-world data, this study evaluates the use of ADCs over a decade across six University of California (UC) medical centers, focusing on the incidence of neutropenia-related adverse effects and associated clinical outcomes. Methods: A real-world retrospective study utilizing UC Health Data Warehouse records of patients receiving at least one dose of the ten most-used ADCs at one of the 6 UC hospitals between 2012 and 2024. The outcomes evaluated in this study were grade 3+ neutropenia and febrile neutropenia (FN) during any treatment cycle, and healthcare utilization outcomes including G-CSF prophylaxis, hospital and ICU admission, and mortality. Multivariate logistic regression was conducted to identify predictors for neutropenia-related events after the first dose of ADC.
Results: Data from 3511 patients (mean ± SD age: 56.7 ± 17.6 years) were analyzed. The most commonly observed cancer types were breast cancer (43.4%), lymphoid, hematopoietic (41.8%), and urinary tract cancer (13.4%). The top three most commonly prescribed ADCs were fam-trastuzumab deruxtecan (22.6%), ado-trastuzumab emtansine (19.4%), and brentuximab vedotin (18.1%). Their respective all-cycle rates of FN were 5.4%, 1.2%, and 10.4%, while grade 3+ neutropenia rates were 16.4%, 5.1%, and 40.1%. Gemtuzumab ozogamicin and inotuzumab ozogamicin were associated with the highest rates of FN (both 18.1%), and inotuzumab ozogamicin was associated with the highest rates of hospital admissions (27.1%), ICU admissions (3.8%), and deaths (5.2%). Anemia and immunodeficiency disorders were identified as predictors for first-dose FN among patients receiving ADCs.
Conclusions: Real-world data from this large multi-center cohort showed substantial variation in neutropenia-related events across ADCs. As ADC use continues to grow, these findings highlight the need for vigilant monitoring and proactive supportive care.
